Publications
Recently Published Data on Bempedoic Acid
Presentations

Efficacy and Safety of Bempedoic Acid Added to Maximally Tolerated Statins in Patients with Hypercholesterolemia and High Cardiovascular Risk: the CLEAR Wisdom Trial
American College of Cardiology 68th Scientific Session & Expo
Anne Carol Goldberg, MD, FACP, FAHA, FNLA 2019
Phase 3 Evaluation of Bempedoic Acid Added to Ezetimibe in Patients with Elevated
LDL-Cholesterol Receiving No Greater Than Low Dose Statins: CLEAR Tranquility
Oral presentation at: International Symposium on Atherosclerosis. June 2018; Toronto, Canada. Christie M. Ballantyne, Maciej Banach, G.B. John Mancini, Norman E. Lepor, Jeffrey C. Hanselman, Xin Zhao, Lawrence A. Leiter.
Long-term Safety, Tolerability, and Efficacy of Bempedoic Acid vs Placebo in High Cardiovascular Risk Patients with LDL-C Above 1.8 mmol/L on Maximally Tolerated Statin Therapy (CLEAR Harmony)
Oral presentation at: European Society of Cardiology Congress. August 2018; Munich, Germany. Kausik K. Ray, Harold E. Bays, Alberico L. Catapano, Narendra Lalwani, LeAnne T. Bloedon, Lulu Ren Sterling, Christie M. Ballantyne, on behalf of the CLEAR Harmony Steering Committee.
Articles

Safety and Efficacy of Bempedoic Acid to Reduce LDL Cholesterol
N Engl J Med. 2019;380(11):1022-1032. doi:10.1056/NEJMoa1803917. Kausik K. Ray, MD, M.Phil; Harold E. Bays, MD; Alberico L. Catapano, PhD; Narendra D. Lalwani, PhD, MBA; LeAnne T. Bloedon, MS, RD; Lulu R. Sterling, PhD; Paula L. Robinson, MS; Christie M. Ballantyne, MD, et al, for the CLEAR Harmony Trial.
Effect of ETC-1002 on Serum Low-Density Lipoprotein Cholesterol in Hypercholesterolemic Patients Receiving Statin Therapy American Journal of Cardiology. 2016;117(12):1928-1933. Christie M. Ballantyne, MD; James M. McKenney, PharmD; Diane E. MacDougall, MS; Janice R. Margulies, MS; Paula L. Robinson, MS; Jeffrey C. Hanselman, MS; and Narendra D. Lalwani, PhD, MBA.
Liver-Specific ATP-Citrate Lyase Inhibition by Bempedoic Acid Decreases LDL-C and Attenuates Atherosclerosis
Nature Communications. 2016;7:13457. doi:10.1038/ncomms13457. Stephen L. Pinkosky, Roger S. Newton, Emily A. Day, Rebecca J. Ford, Sarka Lhotak, Richard C. Austin, Carolyn M. Birch, Brennan K. Smith, Sergey Filippov, Pieter H.E. Groot, Gregory R. Steinberg, Narendra D. Lalwani.
Treatment with ETC-1002 Alone and in Combination with Ezetimibe Lowers LDL Cholesterol in Hypercholesterolemic Patients With or Without Statin Intolerance
Journal of Clinical Lipidology. 2016;10(3):556-567. Paul D. Thompson, MD; Diane E. MacDougall, MS; Roger S. Newton, PhD; Janice R. Margulies, MS; Jeffrey C. Hanselman, MS; David G. Orloff, MD; James M. McKenney, PharmD; Christie M. Ballantyne, MD.
Use of ETC-1002 to Treat Hypercholesterolemia in Patients With Statin Intolerance
Journal of Clinical Lipidology. 2015;9(3):295-304. Paul D. Thompson, MD; John Rubino, MD; Matther J. Janik, MD; Diane E. MacDougall, MS; Scott J. McBride, MA; Janice R. Margulies, MS; Roger S. Newton, PhD.
 
Get alerts about ESPERION and when new publications become available